Share of Cost, Antifungal Therapy Could Benefit Nearly 5 Million Asthmatics Worldwide

Tuesday, Dec. 31st 2013 9:00 AM

An estimated 4,837,000 asthmatics with allergic bronchopulmonary aspergillosis (ABPA) could benefit substantially from antifungal treatment, say researchers from the University of Toronto and Manchester University. Their work, published in the journal Medical Mycology, has also re-estimated the total number of asthmatics worldwide – to reveal a staggering 193 million sufferers.

Posted on Tuesday, Dec. 31st 2013 9:00 AM | by Share of Cost | in Share of Cost | Comments Off on Share of Cost, Antifungal Therapy Could Benefit Nearly 5 Million Asthmatics Worldwide